[go: up one dir, main page]

WO2022067269A3 - Antibodies against sars-cov-2 - Google Patents

Antibodies against sars-cov-2 Download PDF

Info

Publication number
WO2022067269A3
WO2022067269A3 PCT/US2021/052481 US2021052481W WO2022067269A3 WO 2022067269 A3 WO2022067269 A3 WO 2022067269A3 US 2021052481 W US2021052481 W US 2021052481W WO 2022067269 A3 WO2022067269 A3 WO 2022067269A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
antigen
sars
antibody
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/052481
Other languages
French (fr)
Other versions
WO2022067269A2 (en
Inventor
Davide Corti
Anna De Marco
Matteo Samuele PIZZUTO
Barbara GUARINO
Florian LEMPP
Alex Chen
Laura ROSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Original Assignee
Humabs Biomed SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA filed Critical Humabs Biomed SA
Priority to CA3194162A priority Critical patent/CA3194162A1/en
Priority to JP2023544186A priority patent/JP2023545322A/en
Priority to EP21806447.5A priority patent/EP4217385A2/en
Priority to BR112023005684A priority patent/BR112023005684A2/en
Publication of WO2022067269A2 publication Critical patent/WO2022067269A2/en
Publication of WO2022067269A3 publication Critical patent/WO2022067269A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. In certain embodiments, an antibody or antigen-binding fragment is capable of binding to a SARS-CoV-2 spike protein in the N-terminal domain (NTD). Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors that comprise a polynucleotide, host cells that express an antibody or antigen-binding fragment, pharmaceutical compositions, and methods for treating or diagnosing a SARS-CoV-2 infection.
PCT/US2021/052481 2020-09-28 2021-09-28 Antibodies against sars-cov-2 Ceased WO2022067269A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA3194162A CA3194162A1 (en) 2020-09-28 2021-09-28 Antibodies against sars-cov-2
JP2023544186A JP2023545322A (en) 2020-09-28 2021-09-28 Antibodies against SARS-COV-2
EP21806447.5A EP4217385A2 (en) 2020-09-28 2021-09-28 Antibodies against sars-cov-2
BR112023005684A BR112023005684A2 (en) 2020-09-28 2021-09-28 ANTIBODIES AGAINST SARS-COV-2

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202063084501P 2020-09-28 2020-09-28
US63/084,501 2020-09-28
US202063111435P 2020-11-09 2020-11-09
US63/111,435 2020-11-09
US202063112505P 2020-11-11 2020-11-11
US63/112,505 2020-11-11
US202063119545P 2020-11-30 2020-11-30
US63/119,545 2020-11-30
US202163137112P 2021-01-13 2021-01-13
US63/137,112 2021-01-13
US202163170356P 2021-04-02 2021-04-02
US63/170,356 2021-04-02

Publications (2)

Publication Number Publication Date
WO2022067269A2 WO2022067269A2 (en) 2022-03-31
WO2022067269A3 true WO2022067269A3 (en) 2022-06-23

Family

ID=78599130

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/052481 Ceased WO2022067269A2 (en) 2020-09-28 2021-09-28 Antibodies against sars-cov-2

Country Status (5)

Country Link
EP (1) EP4217385A2 (en)
JP (1) JP2023545322A (en)
BR (1) BR112023005684A2 (en)
CA (1) CA3194162A1 (en)
WO (1) WO2022067269A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023201256A1 (en) * 2022-04-12 2023-10-19 Vir Biotechnology, Inc. High dose antibody therapies for sars-cov-2 infection
CN114805564B (en) * 2022-06-10 2023-06-06 郑州大学 Monoclonal antibody specifically recognizing SARS-CoV-2 S protein NTD region and its application
WO2024036313A2 (en) * 2022-08-12 2024-02-15 The Rockefeller University Anti-sars-cov-2 antibodies and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303280A (en) * 2020-03-22 2020-06-19 中国人民解放军军事科学院军事医学研究院 High neutralizing activity anti-SARS-CoV-2 fully human monoclonal antibody and its application

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ATE303445T1 (en) 1999-10-04 2005-09-15 Medicago Inc METHOD FOR REGULATION OF TRANSCRIPTION OF FOREIGN GENES IN THE PRESENCE OF NITROGEN
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
CA2540138C (en) 2003-09-24 2013-07-30 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody against human insulin-like growth factor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
DK3089994T3 (en) 2013-12-30 2022-07-04 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof
JP6587696B2 (en) 2015-05-13 2019-10-09 ズムトール バイオロジクス、インコーポレイテッド Afucosylated proteins, cells expressing said proteins, and related methods
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine Antibodies with functional domains in the elbow region
MA50188A (en) 2017-09-22 2021-06-02 Wuxi Biologics Ireland Ltd NEW BISPECIFIC POLYPEPTIDIC COMPLEXES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303280A (en) * 2020-03-22 2020-06-19 中国人民解放军军事科学院军事医学研究院 High neutralizing activity anti-SARS-CoV-2 fully human monoclonal antibody and its application

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHI XIANGYANG ET AL: "A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2", SCIENCE, vol. 369, no. 6504, 7 August 2020 (2020-08-07), US, pages 650 - 655, XP055850542, ISSN: 0036-8075, DOI: 10.1126/science.abc6952 *
EROSHENKO NIKOLAI ET AL: "Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 38, no. 7, 5 June 2020 (2020-06-05), pages 789 - 791, XP037187546, ISSN: 1087-0156, [retrieved on 20200605], DOI: 10.1038/S41587-020-0577-1 *
F. MIMOTO ET AL: "Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131", PROTEIN ENGINEERING DESIGN AND SELECTION, vol. 26, no. 10, 5 June 2013 (2013-06-05), pages 589 - 598, XP055087986, ISSN: 1741-0126, DOI: 10.1093/protein/gzt022 *
KEVIN O. SAUNDERS ET AL: "Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life", FRONTIERS IN IMMUNOLOGY, vol. 10, 1 January 2019 (2019-01-01), pages 1296, XP055654839, DOI: 10.3389/fimmu.2019.01296 *
PINTO DORA ET AL: "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 583, no. 7815, 18 May 2020 (2020-05-18), pages 290 - 295, XP037289888, ISSN: 0028-0836, [retrieved on 20200518], DOI: 10.1038/S41586-020-2349-Y *
SHI RUI ET AL: "A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 584, no. 7819, 26 May 2020 (2020-05-26), pages 120 - 124, XP037211681, ISSN: 0028-0836, [retrieved on 20200526], DOI: 10.1038/S41586-020-2381-Y *
TORTORICI M ALEJANDRA ET AL: "Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms", SCIENCE, 24 September 2020 (2020-09-24), United States, pages 950 - 957, XP055794998, Retrieved from the Internet <URL:https://science.sciencemag.org/content/sci/370/6519/950.full.pdf> [retrieved on 20210414], DOI: 10.1126/science.abe3354 *
ZHANG LI ET AL: "A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2", BIORXIV, 23 September 2020 (2020-09-23), pages 1 - 18, XP055876862, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.09.23.309294v1.full.pdf> [retrieved on 20220107], DOI: 10.1101/2020.09.23.309294 *

Also Published As

Publication number Publication date
WO2022067269A2 (en) 2022-03-31
EP4217385A2 (en) 2023-08-02
JP2023545322A (en) 2023-10-27
CA3194162A1 (en) 2022-03-31
BR112023005684A2 (en) 2023-11-07

Similar Documents

Publication Publication Date Title
EP4245373A3 (en) Antibodies against sars-cov-2
BR112022015374A2 (en) ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USE THEREOF
BR112022020706A2 (en) ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF THEIR USE
PH12022500020A1 (en) Antibodies against sars-cov-2
WO2022067269A3 (en) Antibodies against sars-cov-2
WO2019165122A8 (en) Neutralizing antibodies to hiv-1 env and their use
MY197648A (en) Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2021018859A3 (en) Antibodies binding to gprc5d
NZ734803A (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
PH12022550056A1 (en) Dll3-targeting antibodies and uses thereof
CR20220646A (en) Sars-cov-2 antibodies and methods of selecting and using the same
MX2023009244A (en) Antibodies targeting the spike protein of coronaviruses.
SA523451800B1 (en) Anti-sirp-alpha antibodies
WO2022032003A3 (en) Anti-claudin 18.2 antibodies and uses thereof
BRPI0606790C1 (en) isolated human monoclonal antibody or antigen binding portion thereof, composition, expression vector, transgenic microorganism, prokaryotic host cell, kit, and, use of an isolated human monoclonal antibody or antigen binding portion thereof, or a composition
WO2020172621A8 (en) Cd33 antibodies and methods of using the same to treat cancer
ZA202201464B (en) Anti-tigit antibodies and application thereof
WO2022020234A3 (en) Immunoassay for sars-cov-2 neutralizing antibodies and materials therefor
WO2022108976A3 (en) Anti-gpa33 multi-specific antibodies and uses thereof
BR112021017860A2 (en) Isolated antibody or antibody fragment specific to human c5ar, nucleic acid composition, vector composition, host cell and pharmaceutical composition
MX2022012021A (en) Autonomous knob domain peptides.
WO2024020590A3 (en) Antigen binding molecules targeting thymic stromal lymphopoietin (tslp)
ZA202308460B (en) Anti-pd-1 antibody and use thereof
WO2022159839A8 (en) Monoclonal antibodies against coronaviruses and uses thereof

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2023544186

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3194162

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023005684

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2021806447

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021806447

Country of ref document: EP

Effective date: 20230428

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21806447

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112023005684

Country of ref document: BR

Free format text: APRESENTAR NOVO CONTEUDO ELETRONICO DE LISTAGEM DE SEQUENCIAS BIOLOGICAS, UMA VEZ QUE FOI VERIFICADA DIVERGENCIA EM CAMPO 110 E NAO SE ENCONTRA NO FORMATO OMPI ST.25, PADRONIZADO PELA PORTARIA INPI 56/2022.

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112023005684

Country of ref document: BR

Free format text: COM BASE NA PORTARIA INPI 56, DE 27/12/2021, APRESENTAR, EM ATE 60 (SESSENTA) DIAS, NOVO CONTEUDO DE LISTAGEM DE SEQUENCIAS, POIS OS CONTEUDOS APRESENTADOS ENCONTRAM-SE FORA DO PADRAO OMPI ST.25.

ENP Entry into the national phase

Ref document number: 112023005684

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230328

WWW Wipo information: withdrawn in national office

Ref document number: 2021806447

Country of ref document: EP